Loading...
•
Mar 31
Nektar Q1 2025 Earnings Report
Nektar Therapeutics reported its first quarter 2025 financial results, showing a decrease in revenue due to the sale of its manufacturing facility and an increase in net loss.
Key Takeaways
Nektar Therapeutics reported a net loss of $50.9 million for the first quarter of 2025, or $0.24 per share, compared to a net loss of $36.8 million, or $0.19 per share, in the same period last year. Total revenue decreased to $10.5 million from $21.6 million in Q1 2024, primarily due to the sale of the Huntsville manufacturing facility. Operating costs and expenses decreased slightly to $55.0 million.
Revenue for Q1 2025 was $10.5 million, a decrease from $21.6 million in Q1 2024, primarily due to the sale of the Huntsville manufacturing facility.
Net loss for Q1 2025 was $50.9 million, or $0.24 per share, compared to a net loss of $36.8 million, or $0.19 per share, in Q1 2024.
Cash and investments in marketable securities stood at $220.7 million as of March 31, 2025, expected to support operations into Q4 2026.
R&D expense increased to $30.5 million in Q1 2025, primarily due to increased development of rezpegaldesleukin.
Nektar
Nektar
Forward Guidance
Nektar Therapeutics expects to report topline data from the Phase 2 study of rezpegaldesleukin in atopic dermatitis in June 2025, followed by data from the alopecia areata study in December 2025. The company is also advancing its NKTR-0165 and NKTR-0166 programs.
Positive Outlook
- Topline data from Phase 2 study of rezpegaldesleukin in atopic dermatitis expected in June 2025.
- Topline data from Phase 2 study of rezpegaldesleukin in alopecia areata expected in December 2025.
- IND-enabling work for NKTR-0165, a unique antibody targeting the TNFR2 receptor, is on track for submission by year-end.
- Significant progress on new bispecific antibody, NKTR-0166, advancing into preclinical studies.
- Cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026.
Challenges Ahead
- Revenue decreased year over year due to the sale of the Huntsville manufacturing facility.
- Increased R&D expense primarily due to the development of rezpegaldesleukin.
- Increased G&A expense due to an increase in legal expenses.
- Incurred a $4.5 million non-cash loss from the equity method investment in Gannet BioChem.
- The company's actual results may differ materially from forward-looking statements due to inherent uncertainties, risks, and changes in circumstances.